Fighting talk
April 2, 2015 | Cancer
One thing that grasps my interest is how society has adopted military style language when talking about cancer
Treatments are described as “defending” or “protecting” whilst cancer patients themselves are “fighters” who “battle” to “beat” the disease. These abstract metaphors of war are used in an attempt to articulate that cancer is a very emotional experience for all involved.
This terminology is intriguing to me, as whilst widely recognised as persuasive, it is also considered controversial. War-like analogies suggest that there will be a “winner”, “loser”, and a “battlefield”. Sadly there are hundreds of types of cancer, and short of resection, there is no definitive cure for any of them. Many patients inevitably end up the “loser” as they endure a “battle” against symptoms of the disease, and the side effects of therapy – which all too often only gains a few more months PFS before the “fight” is “lost”. Perhaps more poignantly, their own bodies are the “battlefield” where this all takes place. I have to ask myself, how do progressed metastatic patients feel anything other than failure when we talk about the disease in this way?
When I’ve personally conducted interviews with medical professionals and patients alike, I hear time and time again their aversion to this style of language. Oncologists have even told me that in medical school they were taught to actively avoid using this vocabulary, and as a result they are unresponsive to any type of marketing materials delivered in this style.
So why, when companies are spending so much time and resources into researching effective messaging, are we continuing to use language that knowingly disengages the target audience? As researchers we know that it’s imperative to ensure that brand messaging speaks directly, and appropriately, to our target audience – and sometimes when conducting research that’s not always just about what the respondent says but rather, how they say it. By including some extra language profiling questions and completing an extra step of analysis when conducting market research, we can determine what segments are likely to exhibit a particular trend of language compared to another segment. The value to this insight is that our language is usually indicative of our behaviour; thus providing an extra layer of understanding into the minds of customers in terms of how they might behave in a particular context, which can inform both communications and sales materials.
Knowing what language ‘works’ for different customers can bring to life the other key factors that are relevant to each audience segment – which not only increases buy-in at implementation but also tailors the communication for optimal outcomes.
With approximately 100 projects conducted in oncology within the last 2 years, it’s the single largest therapeutic area studied at the Research Partnership, and it is clear to see that advances in detecting, diagnosing, and treating cancer have evolved – and are continuing to evolve at a significant rate. Perhaps it’s time we also evolve the way we talk about it, ensuring that we speak in language relevant to the target audience, avoid the “fighting talk” clichés and start using unique positive terminology to talk about “life beyond cancer”?
Research Partnership is one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges.Find out more here: http://bit.ly/1IxUzjW
This content was provided by Research Partnership
Company Details
Latest Content from Research Partnership
Research conducted for Johnson and Johnson published in scientific journal
Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.
Connecting our Inizio Advisory capabilities to help a client address a threat to the brand, guide strategy and improve brand performance
The challenge Our client knew that prescribing of a key brand in a major market had slowed and needed to understand which patient segments were impacted so they could address...
Autoimmune conditions: Living With syndicated patient reports
The prevalence of autoimmune conditions is increasing, and despite significant advancements in treatments, individuals affected by these diseases may not be receiving the most effective management and care. In our...
How we elevated HCP market research engagement and insights using AI avatars for an immersive experience
Our client required an effective strategy for promoting discussions about self-paid vaccines with healthcare professionals (HCPs) during patient consultations. The conventional method of conducting market research would typically only deliver...
How we provided comprehensive real-world patient data for PAH using Therapy Watch, our syndicated market tracking solution
PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such...
The risk of replicating social bias in synthetic patient data – The need for human intelligence partnered with AI
Authored by Paul Reed and Anabelle Gall
Latest European developments and new talent at Research Partnership
Angela Duffy has been appointed as Managing Director for our European based ad hoc research teams. Angela has been an integral part of Research Partnership for 19 years, witnessing its...
New syndicated report – Living with Ulcerative Colitis 2024
Living with Ulcerative Colitis (UC) is a new syndicated patient report that presents valuable insights into the unmet needs and the burden experienced by patients living with UC. The report...
Webcast: AI in MRX: Harnessing the power of AI + people
Artificial intelligence (AI) in market research has surged in recent years, with a flow of innovative tools and techniques which have the potential to revolutionize the landscape. But to unlock...
Navigating challenges of MedTech research with rare-disease patients
Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk's Magazine.